Sam Wertheimer
Président chez Poliwogg Regenerative Medicine Fund, Inc.
Profil
Sam P.
Wertheimer is the founder of Poliwogg, Inc. (founded in 2012).
He is currently the Chairman & Executive Vice President of Poliwogg Regenerative Medicine Fund, Inc. and the Chief Investment Officer, EVP & Managing Director of Poliwogg Advisers LLC.
Dr. Wertheimer has held former positions as Chairman & Chief Executive Officer of Brookline Capital Acquisition Corp., Director of Corus Pharma, Inc. (2001-2006), Director of Salmedix, Inc. (2004-2005), Director of ChemoCentryx, Inc. (2001-2011), Director of Biodel, Inc. (2006-2009), Director of Cerimon Pharmaceuticals, Inc., Director of InteKrin Therapeutics, Inc. (2007-2010), Director-Industrial Liaison of New York University School of Medicine Foundation (1998-2000), Director of NeurAxon, Inc. (2007-2010), Director of Apexigen, Inc. (2022-2023), and Principal of OrbiMed Advisors Private Equity (2000-2011).
He has an undergraduate degree from The Johns Hopkins University, a graduate degree from Yale University, and a doctorate degree from New York University.
Postes actifs de Sam Wertheimer
| Sociétés | Poste | Début |
|---|---|---|
Poliwogg Regenerative Medicine Fund, Inc.
 Poliwogg Regenerative Medicine Fund, Inc. Investment Trusts/Mutual FundsMiscellaneous Poliwogg Regenerative Medicine Fund, Inc. operates as a non-diversified, closed-end management investment company that intends to elect to be regulated as a business development company. Its investment and activities are managed by Poliwogg Advisers LLC. The company was founded in 2014 and is headquartered in New York, NY. | Président | - |
Poliwogg Advisers LLC
 Poliwogg Advisers LLC Investment ManagersFinance Part of Poliwogg Services, LLC, Poliwogg Advisers LLC provides investment advice. The company is based in New York, NY. | Directeur en chef des Investissements | 01/01/2014 |
Anciens postes connus de Sam Wertheimer
| Sociétés | Poste | Fin |
|---|---|---|
| APEXIGEN, INC. | Directeur/Membre du Conseil | 23/08/2023 |
| Poliwogg, Inc. | Fondateur | 01/01/2016 |
| CHEMOCENTRYX, INC. | Directeur/Membre du Conseil | 01/01/2011 |
InteKrin Therapeutics, Inc.
 InteKrin Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology InteKrin Therapeutics, Inc. develops and commercializes therapeutics for metabolic and immune disorders. It develops therapeutics for diabetes, insulin resistance and multiple sclerosis. The company was founded by Dennis M. Lanfear and Christos S. Mantzoros in 2005 and is headquartered in Palo Alto, CA. | Directeur/Membre du Conseil | 01/01/2010 |
NeurAxon, Inc.
 NeurAxon, Inc. Miscellaneous Commercial ServicesCommercial Services NeurAxon, Inc. is engaged in the research and development of growing and unmet needs for chronic pain management. It is focused on developing pain therapeutics targeting neuronal Nitric Oxide Synthase (nNOS) inhibitors. The companyw as founded in 2004 and is headquartered in Mississauga, ON. | Directeur/Membre du Conseil | 01/01/2010 |
Formation de Sam Wertheimer
| New York University | Doctorate Degree |
| Yale University | Graduate Degree |
| The Johns Hopkins University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| APEXIGEN, INC. | Health Technology |
| Entreprise privées | 13 |
|---|---|
ChemoCentryx, Inc.
 ChemoCentryx, Inc. Pharmaceuticals: MajorHealth Technology ChemoCentryx, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in San Carlos, CA. | Health Technology |
Corus Pharma, Inc.
 Corus Pharma, Inc. Pharmaceuticals: MajorHealth Technology Corus Pharma, Inc. develops drugs to treat needs in infectious diseases and respiratory areas. The firm's core competencies reside in the identification of drugs, rapid clinical development, and FDA approval of its products. The firm was founded in January 2001 by A. Bruce Montgomery and is headquartered in Seattle, WA. | Health Technology |
Biodel, Inc.
 Biodel, Inc. Pharmaceuticals: MajorHealth Technology Biodel, Inc. is a pharmaceutical company, which develops novel formulations of already approved therapeutics to treat endocrine disorders such as diabetes and osteoporosis. The company develops product candidates by applying formulation technologies to existing drugs in order to improve their therapeutic profiles. Biodel was founded by Solomon S. Steiner and Erik Steiner on December 3, 2003 and is headquartered in Danbury, CT. | Health Technology |
OrbiMed Advisors Private Equity
 OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | Finance |
InteKrin Therapeutics, Inc.
InteKrin Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology InteKrin Therapeutics, Inc. develops and commercializes therapeutics for metabolic and immune disorders. It develops therapeutics for diabetes, insulin resistance and multiple sclerosis. The company was founded by Dennis M. Lanfear and Christos S. Mantzoros in 2005 and is headquartered in Palo Alto, CA. | Health Technology |
NeurAxon, Inc.
NeurAxon, Inc. Miscellaneous Commercial ServicesCommercial Services NeurAxon, Inc. is engaged in the research and development of growing and unmet needs for chronic pain management. It is focused on developing pain therapeutics targeting neuronal Nitric Oxide Synthase (nNOS) inhibitors. The companyw as founded in 2004 and is headquartered in Mississauga, ON. | Commercial Services |
| New York University School of Medicine Foundation | |
Cerimon Pharmaceuticals, Inc.
 Cerimon Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Cerimon Pharmaceuticals, Inc. developed and distributed biopharmaceutical products. It developed Simulect, a monoclonal antibody for the treatment of moderate-to-severe and steroid-refractory ulcerative colitis; diclofenac sodium, a non-steroidal anti-inflammatory drug that are used to treat various pains, included pain due to musculoskeletal injuries and lower back pain; and topical diclofenac sodium patch products. The company was founded by Paul J. Sekhri, Ansbert Gadicke, and Luke Evnin in November 2004 and was headquartered in South San Francisco, CA. | Health Technology |
Poliwogg Regenerative Medicine Fund, Inc.
Poliwogg Regenerative Medicine Fund, Inc. Investment Trusts/Mutual FundsMiscellaneous Poliwogg Regenerative Medicine Fund, Inc. operates as a non-diversified, closed-end management investment company that intends to elect to be regulated as a business development company. Its investment and activities are managed by Poliwogg Advisers LLC. The company was founded in 2014 and is headquartered in New York, NY. | Miscellaneous |
Poliwogg Advisers LLC
Poliwogg Advisers LLC Investment ManagersFinance Part of Poliwogg Services, LLC, Poliwogg Advisers LLC provides investment advice. The company is based in New York, NY. | Finance |
Brookline Capital Acquisition Corp.
 Brookline Capital Acquisition Corp. Financial ConglomeratesFinance Brookline Capital Acquisition Corp. is a blank check company which intends to focus its search on companies in the life sciences industry. It was formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. The company was founded on May 27, 2020 and is headquartered in New York, NY. | Finance |
Salmedix, Inc.
 Salmedix, Inc. Pharmaceuticals: MajorHealth Technology Salmedix, Inc. develops oncology and small molecule drugs to treat hematological malignancies. The company's product, Treanda, is currently in Phase II clinical trials in the United States and Canada for the treatment of indolent (slowly progressing) non-Hodgkin's lymphoma. It was founded in 2000 and is located in San Diego, CA. | Health Technology |
| Poliwogg, Inc. |
